Advertisement

Current Diabetes Reports

, Volume 5, Issue 1, pp 70–75 | Cite as

The evolving role of inflammation in obesity and the metabolic syndrome

  • Yong-Ho Lee
  • Richard E. Pratley
Article

Abstract

Advances in adipose tissue biology over the past 10 years have led to an improved understanding of the mechanisms linking obesity with the metabolic syndrome and other complications. Obesity is characterized by a chronic, systemic low-grade state of inflammation. Biomarkers of inflammation, such as the leukocyte count, tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and C-reactive protein, are increased in obesity, associated with insulin resistance, and predict the development of type 2 diabetes and cardiovascular disease. It is now clear that the adipocyte is an active participant in the generation of the inflammatory state in obesity. Adipocytes secrete a variety of cytokines, including IL-6 and TNF-α, that promote inflammation. Moreover, recent studies suggest that obesity is associated with an increase in adipose tissue macrophages, which also participate in the inflammatory process through the elaboration of cytokines. An improved understanding of the role of adipose tissue in the activation of inflammatory pathways may suggest novel treatment and prevention strategies aimed at reducing obesity-associated morbidities and mortality.

Keywords

Obesity Insulin Resistance Adipose Tissue Metabolic Syndrome Insulin Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.PubMedCrossRefGoogle Scholar
  2. 2.
    Pi-Sunyer FX: The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002, 10(suppl 2):97S-104S.PubMedGoogle Scholar
  3. 3.
    Stein CJ, Colditz GA: The epidemic of obesity. J Clin Endocrinol Metab 2004, 89:2522–2525.PubMedCrossRefGoogle Scholar
  4. 4.
    Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.PubMedCrossRefGoogle Scholar
  5. 5.
    Rajala MW, Scherer PE: Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation and atherosclerosis. Endocrinology 2003, 144:3765–3773.PubMedCrossRefGoogle Scholar
  6. 6.
    Pratley RE, Wilson C, Bogardus C: Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender. Obes Res 1995, 3:563–571.PubMedGoogle Scholar
  7. 7.
    Vozarova B, Weyer C, Hanson K, et al.: Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001, 9:414–417.PubMedCrossRefGoogle Scholar
  8. 8.
    Hotamisligil G, Spiegelman BM: Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43:1271–1278.PubMedCrossRefGoogle Scholar
  9. 9.
    Castell JV, Gomez-Lechon MJ, David M, et al.: Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179–1186.PubMedCrossRefGoogle Scholar
  10. 10.
    Weinhold B, Bader A, Poli V, Ruther U: Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 1997, 325:617–621.PubMedGoogle Scholar
  11. 11.
    Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131–2135.PubMedCrossRefGoogle Scholar
  12. 12.
    Weyer C, Yudkin JS, Stehouwer CD, et al.: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002, 161:233–242.PubMedCrossRefGoogle Scholar
  13. 13.
    Leinonen E, Hurt-Camejo E, Wiklund O: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003, 166:387–394.PubMedCrossRefGoogle Scholar
  14. 14.
    Yudkin JS: Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003, 27(suppl_3):S25-S28.PubMedCrossRefGoogle Scholar
  15. 15.
    Weyer C, Tataranni PA, Pratley RE: Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000, 23:779–785.PubMedCrossRefGoogle Scholar
  16. 16.
    Nagi DK, Tracy R, Pratley R: Relationship of hepatic and peripheral insulin resistance with plasminogen activator-1 in Pima Indians. Metabolism 1996, 45:1243–1247.PubMedCrossRefGoogle Scholar
  17. 17.
    Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993, 259:87–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610–614.PubMedCrossRefGoogle Scholar
  19. 19.
    Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001, 7:1138–1143.PubMedCrossRefGoogle Scholar
  20. 20.
    Aguirre V, Uchida T, Yenush L, et al.: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275:9047–9054.PubMedCrossRefGoogle Scholar
  21. 21.
    Hotamisligil GS, Peraldi P, Budavari A, et al.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFalpha- and obesity-induced insulin resistance. Science 1996, 271:665–668.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirosumi J, Tuncman G, Chang L, et al.: A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333–336.PubMedCrossRefGoogle Scholar
  23. 23.
    Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286–1292.PubMedCrossRefGoogle Scholar
  24. 24.
    Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649–1652.PubMedCrossRefGoogle Scholar
  25. 25.
    Duncan BB, Schmidt MI, Pankow JS, et al.: Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799–1805.PubMedCrossRefGoogle Scholar
  26. 26.
    Muller S, Martin S, Koenig W, et al.: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute phase proteins but not TNF-alpha or its receptors. Diabetologia 2002, 45:805–812.PubMedCrossRefGoogle Scholar
  27. 27.
    Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143.PubMedCrossRefGoogle Scholar
  28. 28.
    Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  29. 29.
    Kaplan RC, Frishman WH: Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 2001, 3:326–332.PubMedCrossRefGoogle Scholar
  30. 30.
    Chrysohoou C, Pitsavos C, Panagiotakos DB, et al.: Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens 2004, 17:568–573.PubMedCrossRefGoogle Scholar
  31. 31.
    Vozarova B, Weyer C, Lindsay RS, et al.: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:455–461.PubMedCrossRefGoogle Scholar
  32. 32.
    Kannel WB, Anderson K, Wilson PW: White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 1992, 267:1253–1256.PubMedCrossRefGoogle Scholar
  33. 33.
    Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813–1818.PubMedGoogle Scholar
  34. 34.
    Maffei M, Fei H, Lee GH, et al.: Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 1995, 92:6957–6960.PubMedCrossRefGoogle Scholar
  35. 35.
    Maffei M, Halaas J, Ravussin E, et al.: Leptin levels in human and rodent: measurement of plasma leptin and obRNA in obese and weight-reduced subjects. Nat Med 1995, 1:1155–1161.PubMedCrossRefGoogle Scholar
  36. 36.
    Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286–289.PubMedCrossRefGoogle Scholar
  37. 37.
    Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930–1935.PubMedCrossRefGoogle Scholar
  38. 38.
    Klaus S, Keijer J: Gene expression profiling of adipose tissue: individual, depot-dependent, and sex-dependent variabilities. Nutrition 2004, 20:115–120.PubMedCrossRefGoogle Scholar
  39. 39.
    Soukas A, Socci ND, Saatkamp BD, et al.: Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 2001, 276:34167–34174.PubMedCrossRefGoogle Scholar
  40. 40.
    Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830. This study showed that adipose tissue resident macrophages play an active role in obesity and that macrophage-specific gene expression and related inflammatory markers may contribute to the development of obesity-induced insulin resistance.PubMedCrossRefGoogle Scholar
  41. 41.
    Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808. In this study adipose tissue macrophages were significantly and positively associated with adipocyte size as well as body mass and were responsible for a substantial fraction of adipose tissue secretion of major proinflammatory factors such as TNF-α, IL-6, and iNOS.PubMedCrossRefGoogle Scholar
  42. 42.
    Libby P: Changing concepts of atherogenesis. J Intern Med 2000, 247:349–358.PubMedCrossRefGoogle Scholar
  43. 43.
    Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195–2200.PubMedCrossRefGoogle Scholar
  44. 44.
    Watanabe Y, Sunayama S, Shimada K, et al.: Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000, 7:159–163.PubMedGoogle Scholar
  45. 45.
    Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes 2002, 51:2796–2803.PubMedCrossRefGoogle Scholar
  46. 46.
    Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365–371.PubMedGoogle Scholar
  47. 47.
    Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673–1677.PubMedCrossRefGoogle Scholar
  48. 48.
    Kim JK, Kim YJ, Fillmore JJ, et al.: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437–446.PubMedCrossRefGoogle Scholar
  49. 49.
    Hundal RS, Petersen KF, Mayerson AB, et al.: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109:1321–1326.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Yong-Ho Lee
    • 1
  • Richard E. Pratley
    • 1
  1. 1.Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology and Metabolism, Department of MedicineUniversity of Vermont College of MedicineBurlingtonUSA

Personalised recommendations